Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 2Solid Tumor Cancer 1Ovarian Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

pembrolizumab 166Nivolumab 111Ipilimumab 93Dacarbazine 44trametinib 36dabrafenib 34Vemurafenib 33binimetinib 23atezolizumab 23Temozolomide 21cemiplimab 18Paclitaxel 18encorafenib 17spartalizumab 16cobimetinib 15Carboplatin 14talimogene laherparepvec 13Cisplatin 13Cyclophosphamide 12lenvatinib 10Pemetrexed 10Gemcitabine 10Docetaxel 10durvalumab 9Drug Therapy 9Bevacizumab 9tremelimumab 8Injections 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Melanoma × Interleukin-18 × Clear all
NCT00107718 2017-07-27

Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

GlaxoSmithKline

Phase 2 Completed
64 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡